The event will explore how the latest technologies can benefit HPAPI with artificial intelligence and machine learning to hasten risk assessment and validation. We will also be dedicating much deserved attention on emerging therapies including bispecific antibodies, oncolytic viral complexes and hormones. Will the super-high level 5 banding for these biologics prove effective or inept? Are current containment planning and solutions truly ensuing the health of workers? Come and find the answers to these hot topics along with the other unique insights such as continuous manufacturing technologies.
Conference Registration: USD 1999.0